KB Home (NYSE: KBH) fell 6% after quarterly EPS missed estimates, due in part to lower margin. The home builder also trimmed its full year margin forecas ...

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such an offer ...

Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne ...

Wave Life Sciences stock surged over 50% today due to promising data from its Duchenne Muscular Dystrophy candidate WVE-N531.

The stock is trading at $8.18, up $2.84, gaining 53.18% on volume of over 12.4 Million shares. The stock had a days' high of $8.33.

Biotech reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne muscular ...

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, has appointed a new chief artificial ...

* WAVE LIFE SCIENCES LTD - COMMENCED UNDERWRITTEN PUBLIC OFFERING OF $175 MILLION IN AGGREGATE OF ITS ORDINARY SHARES Source text for Eikon: Further company coverage: ...

Metsera revealed Phase 1 data it claims could support a weight-loss medicine that's administered monthly. Elsewhere, Sanofi invested in a struggling biotech and shares of two Duchenne drug developers ...

Wave Life Sciences said new Phase 2 biomarker data for its exon-skipping therapy are promising for certain patients with ...

H.C. Wainwright analyst Andrew Fein has maintained their bullish stance on WVE stock, giving a Buy rating yesterday. Andrew Fein has given his ...

University of Adelaide researchers have developed a new theoretical model to predict the distances ocean waves can travel to ...